Medicinal Chemistry
News and Events - 2004


December

Ms. Shejin Zhu has successfully defended her Master's Thesis in Medicinal Chemistry titled "Non-Camptothecin Topoisomerase I-Targeting Agents" under the guidance of Professor Edmond LaVoie and has accepted an offer of employment from Novartis Pharmaceuticals in Boston, MA. Shejin will begin work as a Scientific Associate I performing research on the synthesis of new pharmaceutical agents.

Professor Longqin Hu and Nilgun Tumer (Biotechnology Center at Cook College) received a Rutgers Academic Excellence Award in the amount of $250,000 for a cooperative proposal to purchase a BIAcore 3000, a state-of-the-art surface plasmon resonance biosensor, for analysis of molecular interactions. This instrument will be shared between Busch and Cook campuses and used by multiple faculty across disciplines, departments, and schools.

November

Longqin Hu, Prodrugs: Effective solutions for solubility, permeability, and targeting challenges (a meeting review). Drugs 7(8), 736-742, 2004.

Longqin Hu, The prodrug approach to better targeting. Current Drug Discovery 4(8), 28-32, 2004.

Alexander L. Ruchelman, Shejin Zhu, Nai Zhou, Angela Liu, Leroy F. Liu, Edmond J. LaVoie, Benzo[i]phenathridines and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity, Abstract of paper, 228th ACS National Meeting, Philadelphia PA, August 22-26, 2004, Abstract publisher: American Chemical Society, Washington, D.C.

Alexander L. Ruchelman, Shejin Zhu, Nai Zhou, Angela Liu, Leroy F. Liu and Edmond J. LaVoie, Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity, Bioorganic & Medicinal Chemistry Letters (14), 5585-5589, 2004

Shejin Zhu (Professor LaVoie's group) presented poster entitled Benzo[i]phenathridines and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity, 228th ACS National Meeting, Philadelphia PA, August 22-26, 2004

Longqin Hu served as a member of the National Cancer Institute Special Emphasis Panel (ZCA1 SRRB-U J1) for the National Cooperative Drug Discovery Groups for Cancer (NCDDG) program, October 27-29, 2004.

August

Members of the Graduate Program in Medicinal Chemistry are saddened to learn of the recent death of Professor Emeritus Leonard Bailey. Professor Bailey retired from this department five years ago and moved to New Hampshire. Our sympathy goes out to Dr. Bailey's entire family and in particular to his wife, Carole.

Alexander L. Ruchelman, Sudhir K. Singh, Angela Liu, Nai Zhou, Leroy F. Liu, and Edmond J. LaVoie Cytotoxicity of 5H-Dibenzo[c,h][1,6]-naphthyridin-6-ones and 6H-Indeno[1,2-c]isoquinolin-5,11-diones in Tumor Cells Sensitive and Resistant to Camptothecin Analogues, Letters in Drug Design and Discovery, 1, 198-202, 2004.

Professor Longqin Hu presented a talk entitled "New Nitroaryl Phosphoramides as Novel Anticancer Prodrugs for Reductive Activation" at a Pharmaceutical Education Associates-sponsored Conference on "Prodrugs: Effective solutions for solubility, permeability, and targeting challenges" on June 28-29, 2004 in Philadelphia, PA.

Professor LaVoie served as a reviewer in late June for the American Cancer Society on the Cancer Drug Discovery Study Section

July

Alexander L. Ruchelman, Tsai-Kun Li, Angela Liu, Leroy F. Liu, and Edmond J. LaVoie, Nitro and Amino Substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Influence on Topoisomerase I-Targeting Activity and Cytotoxicity, Bioorg. Med. Chem., 14, 2000, 3731-3742

Dr. Edmond J. LaVoie was issued a US Patent 6,740,650, Issued May 25, 2004, Heterocyclic cytotoxic agents. This patent covers a series of topoisomerase I targeting agents that have potential clinical utility.

Dr. Longqin Hu and the Department of Pharmaceutical Chemistry jointly sponsored, with the Tristate Chapter of the Chinese American Chemical Society, the CACS Annual Symposium entitled "Frontiers of High Throughput Technologies and Applications" on Saturday, June 5th, 2004 in the Fiber Optics Auditorium, Rutgers University. The one-day event featured an international panel of 12 speakers from both academia and industry and attracted more than 150 attendees.

Professor Edmond J. LaVoie has been asked to serve on the "Cancer Drug Discovery" Grant Review Panel for the American Cancer Society.

March

Professor Longqin Hu (PI) received an NIH grant with Renping Zhou as co-investigator entitled "Structure-Based Design of Eph Receptor Antagonists" (CA104956-01) from National Cancer Institute for the period March 01, 2004-February 28, 2006 in the amount of $279,900.